Docetaxel in the treatment of gastric cancer

Future Oncology

Volumn 2, Issue 5, 2006, Pages 603-620

  Thuss Patience, Peter C ^a   Kretzschmar, Albrecht ^b   Reichardt, Peter ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Section of Pathology   (Germany)

Author keywords

Docetaxel; Gastric cancer; Phase II trials; Phase III trials

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CAPECITABINE; CISPLATIN; CYTOCHROME P450 3A4; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PACLITAXEL; UFT;

ADVANCED CANCER; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ASTHENIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG RESPONSE; DRUG STRUCTURE; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FLUID RETENTION; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HUMAN; HYPERSENSITIVITY REACTION; INFECTION; LIVER TOXICITY; LUNG DISEASE; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SKIN ALLERGY; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMATITIS; STRUCTURE ANALYSIS; THROMBOCYTOPENIA; UNITED STATES; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III; CLINICAL TRIALS, PHASE III AS TOPIC; EPIRUBICIN; FLUOROURACIL; HUMANS; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STOMACH NEOPLASMS; SURVIVAL RATE; TAXOIDS;

EID: 33750120578     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.2.5.603     Document Type: Review

References (101)

1. Parkin DM, Bray F, Ferlay J et al.: Global cancer statistics. CA Cancer J Clin. 5. 74-108 (2005).
2. Crew KD, Neugut AI: Epidemiology of upper gastrointestinal malignancies. Semin. Oncol. 3, 450-464 (2004).
3. Macdonald JS, Smalley SR, Benedetti J et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal. junction. N. Engl. J. Med. 3, 725-730 (2001).
4. Cunningham D, Allum WH, Stenning SP et al: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 355(1), 11-20 (2006).
5. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M: Modified therapy with 5-fluorouracil, doxo-rubicin, and methotrexate in advanced gastric cancer. Cancer 7, 37-41 (1993).
6. Pyrhonen S. Kuitunen T, Nyandoto P, Kouri M: Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br. J. Cancer 7, 587-591 (1995).
7. Scheithauer W, Kornek G, Zeh B: Palliative chemotherapy vs. supportive care in patients with metastatic gastric cancer: a randomized trial. Presented at the 2nd International Conference on Biology, Prevention, and Treatment of GI Malignancy. Köln, Germany, 68 (1995).
8. Glimelius B, Ekstrom K, Hoffman K et al.: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann. Oncol. 8, 163-168 (1997).
9. Webb A, Cunningham D, Scarffe JH et al.: Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J. Clin. Oncol. 15(1), 261-267 (1997).
10. Ross P. Nicolson M, Cunningham D et al.: Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FUin advanced esophagogastric cancer. J. Clin. Oncol. 20(8), 1996-2004 (2002).
11. Vanhoefer U, Rougier P. Wilke H et al.: Final results of a randomized Phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorcruracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract cancer Cooperative Group. J. Clin. Oncol. 18(14), 2648-2657 (2000).
12. Wils JA, Klein HO, Wagener DJ et al: Sequential high-dose methotrexate and fluorouracil combined with doxorubicin - a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J. Clin. Oncol. 9(5), 827-831 (1991).
13. Ajani JA: Evolving chemotherapy for advanced gastric cancer: Oncologist 10(Suppl. 3), S49-S58 (2005).
14. Louvet C, Andre T, Tigaud JM et al: Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J. Clin. Oncol. 20(23), 4543-4548 (2002).
15. Lordick F, Lorenzen S, Stollfuss J et al.: Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid FUFOX regimen) as first-line treatment in metastatic gastric cancer. Br. J. Cancer 93(2), 190-194 (2005).
16. De Vita F, Orditura M, Matano E et al.: A Phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br. J. Cancer 92(9), 1644-1649 (2005).
17. Al-Batran SE, Atmaca A, Hegewisch-Becker S et al.: Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J. Clin. Oncol. 22(4). 658-663 (2004).
18. Kim TW, Kang YK, Ahn JH et al: Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. Ann. Oncol. 13(12). 1893-1898 (2002).
19. Cunningham D, Rao S, Starling N et al.: Randomized multicenter Phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL 2 trial. ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. 24, 18S LBA 4017 (2006).
20. Sakata Y, Ohtsu A, Horikoshi N et al.: Late Phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur. J. Cancer 34(11), 1715-1720 (1998).
21. Ajani JA, Lee FC, Singh DA et al.: Multicenter Phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J. Clin. Oncol. 24(4), 663-7 (2006).
22. Souglakos J, Syrigos K, Potamianou A et al.: Combination of irinotecan (CPT-II) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicenter Phase II trial. Ann. Oncol. 15, 1204-1209 (2004).
23. Boku N, Ohtsu A, Shimada Y et al: Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J. Clin. Oncol. 17, 319-323 (1999).
24. Pozzo C, Barone C. Szanto J et al.: Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized Phase II study. Ann. Oncol.. 15(12), 1773-81 (2004).
25. Bouche O, Raoul JL, Bonnetain F et al.: Randomized multicenter Phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinolecan in patients with previously untreated metastatic gastric canccr: a Fed-eratinn Francophone cle Cancerolngie Digestive Group Study-FFCD. J. Clin. Oncol. 22, 4319-4328, 9803 (2004).
26. Yilmaz U, Oztop I, Alacacioglu A et al.: Irinotecan combined with infusional 5-fluorouracil and high dose leucovorin (FOLFIRI) for the treatment of advanced gastric carcinoma as the first line chemo-therapy. ASCO Annual Meeting Proceedings. Part I of II. J. Clin. Oncol. 23. 16S, 4164 (2004).
27. Dank M, Zaluski J, Barone C et al.: Randomized Phase 3 trial of irinotecan (CPT-11) + 5FU/folinic acid (FA) vs CDDP + 5FU in 1st-line advanced gastric cancer patients ASCO Annual Meeting Proceedings. Part I of II. J. Clin. Oncol. 23, 16S, 4003 (2005).
28. Kollmannsberger C, Quietzsch D, Haag C et al: A Phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br. J. Cancer 83(4), 458-462 (2006).
29. Gadgeel SM, Shields AF, Heilbrun LK et al.: Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. Am. J. Clin. Oncol. 26(1). 37-41 (2003).
30. Al-Batran S, Hartmann JT, Probst S et al.: A randomized Phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP). ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. 24, LBA 4016 (2006).
31. Kang Y, Kang WK, Shin DB et al.: Randomized Phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC), Efficacy and safety results. ASCO Annual Meeting Proceedings Part I. 24, 18S, LBA4018 J. Clin. Oncol.(2006).
32. Shah MA, Ramanathan RK, Ilson D et al.: Final results of a multicenter Phase II study of irinotecan (CPT), cisplatin (CIS), and bevacizumab (BEV) in patients with metastatic gastric or gastroesophageal (GEJ) adenocarcinoma (NCI 6447). ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. 24, 18S, 4020 (2006).
33. Pinto C, Di Fabio, F, Siena S et al.: Phase II study of cetuximab plus FOLFIRI as first-line treatment in patients with unresectable/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (FOLCETUX study), Preliminary results. ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. 24, 18S, 4031 (2006).
34. Bissery MC, Nohynek G, Sanderink GJ, Lavelle F: Docetaxel (Taxotere), a review of preclinical and clinical experience. Part I: preclinical experience. Anticancer Drugs 6(3), 339-355, 363-368 (1995).
35. Rowinsky EK: The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Ann. Rev. Med. 4, 353-374 (2006).
36. Fulton B, Spencer CM: Docetaxel: a review of its pharmacodynamic properties antd therapeutic efficacy in the management of metastatic breast cancer. Drugs 5, 1075-1092 (1996).
37. Grant DS, Williams TL, Zahaczewsky M, Dicker AP: Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int. J. Cancer 104 (1), 121-129 (2003).
38. Geng CX, Zeng ZC, Wang JY: Docetaxel inhibits SMMC-7721 human hepatucellular carinoma cells growth and induces apoptosis. World J. Gastroenterol, 9, 696-700 (2003).
39. Bekaii-Saab TS, Villalona-Calero MA: Preclinical experience with docetaxel in gastrointestinal cancer. Semin. Oncol. 3(Suppl. 4), S3-S9 (2005).
40. Kim R, Minami K, Nishimoto N, Toge T: Enhancement of antitumor effect by intratumoral administration of bax gene in combination with anticancer drugs in gastric cancer. Int. J. Oncol. 180, 363-367 (2006).
41. Bruno R, Riva A, Hine D, Lebecq A, Thomas L: Pharmacokinetic and pharmacodynamic properties of docetaxel: results of Phase I and Phase II trials. Am. J. Health Syst. Pharm. 54 (24 Suppl. 2), S16-S19 (1997).
42. Bruno R, Sanderink GJ: Pharmacokinetics and metabolism of Taxotere (docetaxel). Cancer Surv. 17. 305-313 (1993).
43. Engels FK, Sparreboom A, Mathot RA, Verweij J: Potential for improvement of docetaxel-based chemotherapy: a pharmacological review. Br. J. Cancer 93(2), 173-177 (2005).
44. Bruno R, Hille D, Riva A et al.: Population pharmacokinetics/ pharmacodynamics of docetaxel in Phase II studies in patients with cancer. J. Clin. Oncol. 16(1), 187-196 (2001).
45. Naitoh H, Kawaguch A, Yamamoto H et al.: Measurement of docetaxel concentration in blood and ascites after drip infusion into each vessel and intraperitoneal cavity of gastric cancer. Gan To Kagaku Ryoho. 31(12), 2031-2034 (2004).
46. ten Tije AJ, Loos WJ, Zhao M et al.: Limited cerebrospinal fluid penetration of docetaxel. Anticancer Drugs 15(7), 715-718 (2004).
47. Sulkes A, Smyth J, Sessa C et al.: Docetaxel (Taxotere) in advanced gastric cancer: results of a Phase II clinical trial. EORTC Early Clinical Trials Group. Br. J. Cancer 70(2), 380-383 (1994).
48. Einzig AI, Neuberg D, Remick SC et al.: Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med. Oncol. 13(2), 87-93 (1996).
49. Mavroudis D, Kourousis C, Androulakis N et al.: Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (GCSF), a Phase II trial. Am. J. Clin. Oncol. 23(4), 341-344 (2000).
50. Giuliani F, Gebbia V, De Vita F et al.: Docetaxel as salvage therapy in advanced gastric cancer: a Phase II study of the Gruppo Oncologico Italia Meridionale (G.O.I.M.). Anticancer Res. 23(5b), 4219-4222 (2003).
51. Vanhoefer U, Wilke H, Harstrick A et al.: Phase II study of docetaxel as second-line chemotherapy in metastatic gastric cancer. Proc. Am. Soc. Clin. Oncol. 1163 (1999).
52. Bang YJ, Kang WK, Kang YK et al.: Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a Phase II trial. Jpn J. Clin. Oncol. 32(7), 248-254 (2002).
53. Taguchi T, Sakata Y, Kanamaru R et al.: Late Phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese Cooperative Study Group trial (group A). Gan To Kagaku Ryoho. 25 (12), 1915-1924 (1998).
54. Graziano F, Catalano V, Baidelli AM et al.: A Phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Ann. Oncol. 11(10), 1263-1266 (2000).
55. Lee JL, Ryu MH, Kang HJ et al.: Efficacy and safety study of Docetaxel as salvage chemotherapy in metastatic gastric cancer failing fluoropyrimidine and platinum combination chemotherapy. ASCO Annual Meeting Proceedings Part I of II. J Clin. Oncol 23, 16S, 4220 (2005).
56. Hill BT, Whelan RD, Shellard SA et al.: Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro. Invest. New Drugs 12(3), 169-182 (1994).
57. Constenla M, Garcia-Arroyo R. Lorenzo I et al.: Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a Phase II study. Gastric Cancer 5(3), 142-147 (2002).
58. Chun HG, Puccio CA, Mittelman A: Weekly docetaxel and continuous infusion (CI) 5-fluorouracil (5-FU) in elderly patients (pts) with cancer of the stomach and distal esophagus. Proc. Am. Soc. Clin. Oncol. 2, A162 (1998) (Abstract 645).
59. Jeung HC, Rha SY, Kim YT, Noh SH, Rob JK, Chung HC: A Phase II study of infusional 5-fluorouracil and low-dose leucovorin with docetaxel for advanced gastric cancer. Oncology 70(1), 63-70 (2006).
60. Papakostas P, Tsavdaridis D, Kosmidis P et al.: Combination docetaxel (Taxotere), fluorouracil, and leucovorin (TFL), as first-line chemotherapy in advanced gastric cancer: a Hellenic Cooperative Oncology Group Phase II study. Gastric Cancer 9(1). 26-31 (2001).
61. Thuss-Patience PC, Kretzschmar A, Repp M et al.: Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized Phase II study. J. Clin. Oncol. 23(3), 494-501 (2006).
62. Hawkins R, Cunningham D, Soerbye H et al: Randomized Phase II trial of docetaxel plus irinotecan versus docetaxel plus 5-fluorouracil (5FU) in patients with untreated advanced gastric adenocarcinoma (AGAC). Proc. Am. Soc. Clin. Oncol. 2, A257, 1032 (2003).
63. Park SH, Lee WK, Chung M et al.: Paclitaxel versus docetaxel for advanced gastric cancer: a randomized Phase II trial in combination with infusional 5-fluorouracil. Anticancer Drugs 17(2), 225-229 (2006).
64. Park YH, Ryoo BY, Choi SJ, Kim HT: A Phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer. Br. J. Cancer 90(7), 1329-1333 (2004).
65. Chun JH, Kim HK, Lee JS et al.: Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer. Am. J. Clin. Oncol. 28(2), 188-194 (2005).
66. Kim JG, Sohn SK, Kim DH et al.: Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer. Oncology 68(2-3), 190-195 (2005).
67. Giordano KE, Jatoi A, Stella PJ et al.: North Central Cancer Treatment Group. Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a Phase II study from the North Central Cancer Treatment Group. Ann. Oncol. 17(4),652-656 (2006).
68. Thuss-Patience PC, Kretzschmar A, Dogan Y et al.: Capecitabine and docetaxel for advanced gastric cancer. ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. 24, 18S (2006).
69. Catalano G, Orditura M, Diadema MR et al.: Phase II study of weekly docetaxel and capecitabine in patients with metastatic gastric cancer (GC). ASCO Annual Meeting Proceedings Part I of II. J. Clin. Oncol. 23, 16S, 4207 (2005).
70. Tebutt N, Gebski V, Strickland A et al.: Randomized Phase II study evaluating weekly docetaxel in combination with cisplatin and 5-FU or capecitabine in metastatic oesophago-gastric cancer. ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. 24, 18S-4067 (2006).
71. Yoshida K, Ninomiya M, Takakura N et al.: Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin. Cancer Res. 12(11 Pt 1), 3402-3407 (2006).
72. Ajani JA, Faust J, Ikeda K et al.: Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J. Clin. Oncol. 23(28), 6957-6965 (2005).
73. Chang HM, Kim TW, Yook JH et al.: Phase II study of irinotecan (I) and docetaxel (D) as second line chemotherapy for patients with previously treated advanced gastric cancer (AGC). Proc. Am. Soc. Clin. Oncol. 2, 328 (2003).
74. Enrech S, Gonzalez E, Mendez M et al.: Docetaxel in combination with irinotecan (CPT-11) in locally advanced or metastatic gastric cancer. A Goti Cooperative Spanish Group Study. Proc. Am. Soc. Clin. Oncol. 2, 362 (2003).
75. Park SR, Chun JH, Yu MS et al.: Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma. Br. J. Cancer 94(10), 1402-1406 (2006).
76. Enzinger PC, Clark J, Ryan D et al.: Phase II study of Docetaxel, cisplatin, and irinotecan in advanced gastric cancer. Proc. Am. Soc. Clin. Oncol. (Abstract 4040) and J. Clin. Oncol. 22 (2004).
77. Roth AD, Maibach R, Martinelli G et al.: Docetaxel (Taxotere)-cisplatin (TC), an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann. Oncol. 11(3), 301-306 (2000).
78. Ridwelski K, Gebauer T, Fahlke J et al.: Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann. Oncol. 12(1), 47-51 (2001).
79. Kettner E, Ridwelski K. Keilhoiz U et al.: Docetaxel and cisplatin ceombination chemotherapy foe advanced gastric cancer. Results of two Phase II studies. 37th annual meeting of the Proc. Am. Soc. Clin. Oncol. (2001) (Abstract 657).
80. Park KW, Ahn JS, Park YS et al.: Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer. Cancer Chemother: Pharmacol. (2006).
81. Park SH, Kang WK, Lee HR et al.: Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen. Am. J. Clin. Oncol. 27(5), 477-480 (2004).
82. Kim H, Park JH, Bang SJ et al.: A Phase II study of docetaxel and cisplatin in patients with gastric cancer recurring after or progressing during 5-FU/platinum treatment. Jpn J. Clin. Oncol. 35(12), 727-732 (2005).
83. Kunisaki C, Imada T, Yamada R et al.: Phase II study of docetaxel plus cisplatin as a second-line combined therapy in patients with advanced gastric carcinoma. Anticancer Res.25(4), 2973-2977 (2005).
84. Chun J, Park S, Kim H et al.: Randomized Phase II trial of neoadjuvant vs. adjuvant docetaxel plus cisplatin in patients with locally advanced gastric carcinoma: An interim analysis. ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. 24, 18S, 4030 (2006).
85. Roth AD, Maibach R, Fazio N et al.: 5-Fluorouracil as protracted continuous intravenous infusion can be added to fulldose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a Phase I-II trial. Ann. Oncol. 15(5), 759-764 (2004).
86. Roth AD, Mailbach R, Falk S et al.: Docetaxel-cisplatin-5FU (TCF) versus docetaxel-cisplatin (TC) versus epirubicin-cisplatin-5FU (ECF) as systemic treatment for advanced gastric adenocarcinoma (AGC), a randimized Phase II trial of the Swiss Group for Clinical Cancer research (SAKK). ASCO Annual Meeting Proceedings (Post-Meeting Edition). J. Clin. Oncol. 22, 4020 (2004).
87. Ajani JA. Fodor MB, Tjulandin SA et al.: Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J. Clin. Oncol. 23(24), 5660-5667 (2005).
88. Moiseyenko V, Ajani J, Tjulandin S et al.: Final results of a randomized controlled Phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC). ASCO Annual Meeting Proceedings. 23, 16S, Part I of II, 4002 J. Clin. Oncol. (2005).
89. Park SR, Chun JH, Kim YW et al.: Phase II study of low-dose docetaxel/ fluorouracil/cisplatin in metastatic gastric carcinoma. Am. J. Clin. Oncol. 28(5), 433438 (2005).
90. Oh DY, Kim TY, Kwon JH et al.: Docetaxel + 5-fluorouracil + cisplatin 3-day combination chemotherapy as a first-line treatment in patients with unresectable gastric cancer. Jpn J. Clin. Oncol. 35(7), 380-385 (2005).
91. Kang YK, Kim TW, Chang HM et al.: A Phase I/II trial of Docetaxel, capecitabine and cisplatin as a first line chemotherapy for advanced gastric cancer. Proc. Am. Soc. Clin. Oncol. (Abstract 4066) and J. Clin. Oncol. 22, (2004).
92. Oh SC, Park KH, Choi IK et al.: Docetaxel (Taxotere), cisplatin, UFT, and leucovorin combination chemotherapy in advanced gastric cancer. Br. J. Cancer 92(5), 827-831 (2005).
93. Elsaid A, Elkerm Y: Final results of a randomized Phase III trial of docetaxel, carboplatin and 5-FU versus epirubicin, cisplatin and 5-FU for locally advanced gastric cancer. ASCO Annual Meeting Proceedings Part I of II. J Clin. Oncol. 23, 16S, 4014 (2005).
94. Nguyen S, Rebischung C, Van Ongeval J et al.: Epirubicin-docetaxel in advanced gastric cancer: two Phase II studies as second and first line treatment. Bull. Cancer. 93(1), E1-E6 (2006).
95. Wadler S, Brain C, Catalano P, Einzig AI, Celia D, Benson AB 3rd: Randomized Phase II trial of either fluorouracil, parenteral hydroxyurea, interferon-alpha-2a, and filgrastim or doxorubicin/ docetaxel in patients with advanced gastric cancer with quality-of-life assessment: eastern cooperative oncology group study E6296. Cancer J. 8(3), 282-286 (2002).
96. Lee SH, Kang WK, Park J et al.: Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer. Br. J. Cancer 91(1), 18-22 (2004).
97. Di Lauro L, Belli F, Arena MG et al: Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer. Ann. Oncol. 16(9), 1498-1502 (2005).
98. Papakostas P, Xanthakis J, Tsavdaridis D et al.: Intensive weekly chemotherapy for advanced gastric cancer. ASCO Annual Meeting Proceedings. Part I of II, J. Clin. Oncol. 23, 16S, 4212 (2005).
99. Schinzari G, D'Argento E, Quirino G et al.: Docetaxel and oxaliplatin combination as second-line treatment in patients with advanced gastric cancer. ASCO Annual Meeting Proceedings Part I of II, J. Clin, Oncol. 23, 16S, 4188 (2005).
100. Richards DA, Wilfong L, Reznick D et al.: Phase II multicenter trial of Docetaxel + oxaliplatin in stage IV gastroesophageal and/or stomach cancer. ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol.24, 18S, 4071 (2006).
101. Enzinger PC, Fidas P, Meyerhardt J et al.: Phase II study of bevacizumab and Docetaxel in metastatic esophageal and gastric cancer. ASCO Gastrointestinal Cancers Symposium (2006) (Abstract 68).